ライフサイエンスコーパス: effect modifier

1 days prior to the survey was modeled as the effect modifier.

2 allelic dose were tested, and race was a key effect modifier.

3 rability index neighborhood was tested as an effect modifier.

4 inalized race and ethnicity was tested as an effect modifier.

5 sed social support was tested as a potential effect modifier.

6 We examined prenatal HV as an effect modifier.

7 -economic factors may act as a confounder or effect modifier.

8 ical complications, and might be a treatment effect modifier.

9 al age at birth because it was a significant effect modifier.

10 absence of subgingival calculus was a strong effect modifier.

11 a potential confounder and separately as an effect modifier.

12 nal structural model with sex as a potential effect-modifier.

13 ttention to social factors as confounders or effect modifiers.

14 ainst models with alternative causes or with effect modifiers.

15 city and other demographics were assessed as effect modifiers.

16 d payment type for delivery were assessed as effect modifiers.

17 use of steroid medications were examined as effect modifiers.

18 Region and year comprised random intercept effect modifiers.

19 stinction between confounders, mediators and effect modifiers.

20 ion, and found these factors to be important effect modifiers.

21 ng exposure and immunosuppression regimen as effect modifiers.

22 -regression to examine potential study-level effect modifiers.

23 fects meta-regression to examine study-level effect modifiers.

24 d air travel were included as confounders or effect modifiers.

25 und no influence from the other hypothesized effect modifiers.

26 son, study, and CO methods as covariates and effect modifiers.

27 neity across studies suggests influence from effect modifiers.

28 re undertaken to examine potential treatment effect modifiers.

29 , and in all age groups, with no significant effect modifiers.

30 The models did not adjust for all potential effect modifiers.

31 trations in humans and investigate potential effect modifiers.

32 both biological and social risk factors and effect modifiers.

33 opulation, but age and smoking are important effect modifiers.

34 veral city characteristics were evaluated as effect modifiers.

35 of disease or subgroups of several potential effect modifiers.

36 stment for several potential confounders and effect modifiers.

37 were evaluated as potential confounders and effect modifiers.

38 f kidney disease, suggesting the presence of effect modifiers.

39 Age and comorbidity were effect modifiers.

40 nd drinking patterns are likely to be strong effect modifiers.

41 /neighborhood characteristics that are known effect modifiers.

42 n tests were performed to identify potential effect modifiers.

43 on background, income, and the four possible effect modifiers (adjusted HR 1.55 [95% CI 1.53-1.56]).

44 We tested for diabetes as an effect modifier, adjusting for potential confounders suc

45 ntrations and iron status were considered as effect modifiers, although few studies included such sub

46 In conclusion, age is a major effect modifier among patients with an eGFR of <60 ml/mi

47 nd assessed physical activity as a potential effect modifier and mediator.

48 condary analyses, the influence of important effect modifiers and confounders, such as smoking status

49 treating it as a confounder, sometimes as an effect modifier, and sometimes as a co-exposure.

50 ied analytic plan for exposures, covariates, effect modifiers, and analysis, and the findings were th

51 function, identify important confounders and effect modifiers, and generate and test hypotheses about

52 accine effect on HIV acquisition and vaccine effect modifiers, and nonparametric and semiparametric m

53 cuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogeneti

54 ing, and were not appreciably altered by the effect modifiers, apart from parental allergic disease (

55 role of time post-HCT at immunization as an effect modifier are unknown.

56 past smoking history was also a significant effect modifier as demonstrated by the statistically sig

57 subgroups of the study- and individual-level effect modifiers, but effects were larger in certain sub

58 priori investigations were used to identify effect modifiers/confounders and extreme associations re

59 as used with interaction terms for potential effect modifiers (e.g., age, sex, and socioeconomic stat

60 design, measurements, mechanisms, potential effect modifiers (eg, age), and relevance for public pol

61 nvestigated whether cigarette smoking was an effect modifier for asthma morbidity.

62 or after intervention was withdrawn) was an effect modifier for both adherence to antiretroviral the

63 a dose of oral glucose was not a significant effect modifier for cardiovascular disease risk factors.

64 Pneumonia was a positive effect modifier for deaths from all causes and stroke, w

65 s, and racial differences were a significant effect modifier for EBV IgG status and risk of PTLD.

66 iduals, heavy personal tobacco use may be an effect modifier for O3-associated morbidity.

67 odels were used to assess whether age was an effect modifier for PSEN1 mutation of amyloid B levels a

68 Setting (rural vs urban) was an effect modifier for risk factors including Sm- and Schis

69 Age was a significant effect modifier for the association between PSEN1 mutati

70 no-IBS group, but IBS was not a significant effect modifier for the association.

71 Baseline neurocognitive ability was an effect modifier for the associations of statins with dem

72 stage of labour, and (b) maternal age is an effect modifier for this association.

73 Male sex is an age-specific effect modifier for ulcerated CM by tumor depth.

74 evious biologic exposure, and ethnicity were effect modifiers for biologics and their survival in ass

75 hould, therefore, be considered as potential effect modifiers for KSHV-associated cancers in sub-Saha

76 posure, nail involvement, and ethnicity were effect modifiers for survival in association with treatm

77 FLG mutation and PSE were not effect modifiers for the association between IgE sensiti

78 nformation on emotional demands and possible effect modifiers from job exposure matrices, and covaria

79 minutes after a dose of oral glucose was an effect modifier (group x time x insulin concentration at

80 Our analysis of effect modifiers highlights certain social vulnerabiliti

81 African ancestry and asthma were not effect modifiers; however, exposure to steroid medicatio

82 ed differential association across potential effect modifiers implicated in oxidative stress and incr

83 ment effects to match the distribution of an effect modifier in CPRD.

84 asal colonization has gained attention as an effect modifier in Staphylococcus aureus vaccine trials,

85 Cigarette smoking should be evaluated as an effect modifier in studies of media use and obesity.

86 es or hyperlipidemia, but instead acts as an effect modifier in susceptible populations by increasing

87 addition, it was assessed whether sex was an effect modifier in the association between aspirin dose

88 her neighborhood climate vulnerability is an effect modifier in the Maternal And Developmental Risks

89 Race was examined as an effect modifier in the resident outcome model.

90 for pneumonia admissions that diabetes is an effect modifier in the younger age group, and for COPD i

91 ls were explored as potential confounders or effect modifiers in logistic regression analysis.

92 Age was reported to be an effect-modifier in four randomised controlled trials com

93 Effect modifiers included sex, low job control, high dem

94 Effect modifiers included stress-related measures in pre

95 There were a number of significant effect modifiers, including public insurance, panel reac

96 = 224; P = .049 for interaction) were likely effect modifiers increasing a PPI-CAP association; conve

97 Understanding effect modifiers is important given that any use of aspi

98 ring, and the like), rather than the smaller effect modifier loci that more subtly influence colour.

99 h the survival of each biologic differently (effect modifiers) may inform the decision to choose betw

100 We found that gender is a significant effect modifier of thalamic GABA/Water's relationship wi

101 tudy examined exposure to fluoridation as an effect modifier of the association between breastfeeding

102 expected with SARS-CoV-2 outcomes) and as an effect modifier of the association between influenza vac

103 Gender is an observed effect modifier of the association between loneliness an

104 Psychological status was an effect modifier of the association between standard Inne

105 Alcohol consumption was an effect modifier of the association.

106 Social support was not a significant effect modifier of the associations (social isolation x

107 D cohort, in which FGF-23 level was again an effect modifier of the relationship between plasma ADMA

108 ionally, diabetes was a significant positive effect modifier of the relationship between sleep and se

109 ion, we evaluated aldosterone as a potential effect modifier of these associations.

110 ogic plausibilities that obesity might be an effect modifier of treatment, but supporting evidence fr

111 P24A, CYP27B1, GC, and RXRA were analyzed as effect modifiers of 25(OH)D.

112 variety of phenotypes and implies that major effect modifiers of extreme phenotypes are not uncommon

113 y (FibroPlex) that quantifies predictors and effect modifiers of fibrosis.

114 Further research considering effect modifiers of pollen sensitization, hay fever, ast

115 immunoevasion strategy, and thus may act as effect modifiers of the HSV1-AD association.

116 a, and interferon-gamma, were confounders or effect modifiers of this association between adiponectin

117 d assessed potential confounding factors and effect modifiers of those associations in a large commun

118 ovariates are often used, their potential as effect modifiers often remains unexplored.

119 r cohort designs, and/or with adjustment for effect modifiers or confounders.

120 n iron variables were stratified by possible effect modifiers or hormone receptor status.

121 or health-related factors were confounders, effect modifiers, or irrelevant with regard to understan

122 Only age group was a significant treatment effect modifier (P for interaction, 0.003).

123 ws different depths of the CF with important effect modifiers, performs plurality votes to obtain dec

124 The analyses of the treatment effect modifiers suggested that the intervention had a l

125 A generated effect modifier TDR was applied to identify the optimal

126 posed a comprehensive set of confounders and effect modifiers that need to be considered in future st

127 ew and extracted data on the confounders and effect modifiers that were considered and the approaches

128 transplant as a competing risk and age as an effect modifier, to examine the risk of death associated

129 s suggested that vaccine availability was an effect modifier, underscoring the importance of opportun

130 nd identify clinical or biological treatment effect modifiers, updated data for previously treated pa

131 The strongest effect modifier was place of death for heat, with out-of

132 and explore study-level and individual-level effect modifiers, we conducted an individual participant

133 use-specific mortality and examine potential effect modifiers, we obtained urinary PGE-M levels of 29

134 Identified effect modifiers were also assessed on the basis of over

135 these associations was further examined, and effect modifiers were identified.

136 the mean blood pressure effect adjusted for effect modifiers were performed.

137 the gold-standard estimates when continuous effect modifiers were represented as categorical variabl

138 uding risk of bias assessment) and potential effect modifiers were tested using Cochran's Q Test.

139 Prespecified effect modifiers were tested using multivariable hierarc

140 and pinprick pain sensitivity, as potential effect modifiers, were measured using quantitative senso

141 study variation in unmeasured confounders or effect modifiers, which is markedly reduced if attention

142 treatment (PCI or CABG) and two prespecified effect-modifiers, which were selected on the basis of pr

143 ibe the magnitude and dose-responsiveness of effect modifiers with respect to changes in status.